WhatsApp
backNews Article

Emcure Pharmaceuticals Reports 24% Revenue Growth and 31% EBITDA Rise in Q2 FY27 with Strong Domestic and International Performance

The company raises FY27 revenue growth outlook beyond 20%, driven by broad-based gains in India, Europe, Canada, and emerging markets

Emcure Pharmaceuticals Limited posted a 24% year-on-year increase in revenue to INR 2,820 crores for Q2 FY27, driven by broad-based growth across domestic and international markets. EBITDA rose 31% to INR 575 crores and net profit increased 29% to INR 325 crores, with expanded margins supported by productivity gains and operating leverage. Positive developments include approval and filings of key products and a raised revenue growth outlook for full year FY27 exceeding 20%.

06 Nov 2026|EMCURE+0.70%
Emcure Pharmaceuticals LimitedEMCUREEarnings Call Transcript

Emcure Pharmaceuticals Limited

Earnings Call Transcript

Emcure Pharmaceuticals Limited reported strong financial results for the second quarter of FY27, with revenue reaching INR 2,820 crores, a 24% increase year-on-year. Profitability rose in tandem, with EBITDA growing by 31% to INR 575 crores and profit after tax increasing 29% to INR 325 crores.

The company’s domestic market revenue grew 12% to INR 1,155 crores, marking the second consecutive quarter of double-digit growth driven mainly by women’s health, cardiometabolic, and CNS portfolios.

International business contributed INR 1,665 crores, growing 34.5% year-on-year, with Europe (INR 604 crores), Canada (INR 431 crores), and emerging markets (INR 630 crores) all showing significant gains supported by new product launches and expanded portfolios.

Research and Development expenses totaled INR 111 crores (4% of revenue), with over 20 product approvals during the quarter including liposomal amphotericin B in Brazil and Mexico, bevacizumab in India, and positive recommendations for lenacapavir injection.

The Board approved the amalgamation of two wholly owned subsidiaries as part of a corporate simplification plan, aimed at operational synergies subject to regulatory approvals.

Emcure raised its full year FY27 revenue growth outlook to exceed 20%, up from a previously stated mid-teens projection, supported by ongoing momentum across business segments.

Highlights

  • Revenue for Q2 FY27 increased 24% year-on-year to INR 2,820 crores, with a 9% sequential rise.
  • EBITDA grew 31% to INR 575 crores, with margin expansion to 20.4% driven by productivity and operating leverage.
  • Profit after tax rose 29% to INR 325 crores for the quarter.
  • India business grew 12%, led by strong performance in women’s health, cardiometabolic, CNS, and Consumer Health segments.
  • International markets grew 34.5%, including 36% growth in Europe and 24% in Canada.
  • R&D investment of INR 111 crores (4% of revenue) supported 20+ product approvals, including key regulatory milestones in Brazil, Mexico, India, and filings with the WHO and US FDA for lenacapavir injection.

Key Data Snapshot

Revenue for Q2 FY27INR 2,820 crores
Year-on-year revenue growth24%
Sequential revenue growth9%
EBITDA for Q2 FY27INR 575 crores
EBITDA growth year-on-year31%
EBITDA margin20.4%
Profit after tax for Q2 FY27INR 325 crores
Profit after tax growth year-on-year29%
India business revenueINR 1,155 crores
India business growth year-on-year12%
International business revenueINR 1,665 crores
International business growth year-on-year34.5%
R&D investment for Q2 FY27INR 111 crores
R&D as percentage of revenue4%

Financial performance

  • Emcure reported a 24% year-on-year increase in total revenue to INR 2,820 crores for Q2 FY27, with a sequential increase of 9%.
  • EBITDA grew 31% year-on-year to INR 575 crores, and EBITDA margins expanded by approximately 100 basis points to 20.4%, attributable to productivity improvements and operating leverage.
  • Profit after tax increased 29% to INR 325 crores for the quarter.

Operational performance

  • India business grew 12% year-on-year to INR 1,155 crores, marking the second quarter of double-digit growth, supported by women’s health, cardiometabolic, and CNS product portfolios.
  • Consumer Health products such as Bitter Drops and Galact showed traction, representing an emerging growth engine.
  • International business contributed 59% of total revenue at INR 1,665 crores, growing 34.5% year-on-year driven by base business expansion and new product launches.
  • Europe segment grew 36%, with strong performance in the UK and Continental Europe, including scale-up of liposomal amphotericin B.
  • Canada grew 24%, driven by base business growth and recent launches, with more expected in the second half.
  • Emerging markets grew 41%, supported by expansion in ARV and non-ARV portfolios across Latin America, CIS, Asia, and Africa.

Strategic context

  • Board approved amalgamation of Zuventus Healthcare and Emcutix Biopharmaceuticals with Emcure to simplify group structure and enable operational synergies, subject to necessary approvals.
  • R&D expenditure totaled INR 111 crores, about 4% of revenue, with plans to increase investments in the second half of FY27.
  • Over 20 product approvals were received, including liposomal amphotericin B in Brazil and Mexico and bevacizumab for wet AMD in India.
  • Positive expert committee recommendation for lenacapavir injection for PrEP indication in India, with dossiers filed with WHO and US FDA for other markets.
  • Company raised FY27 full year revenue growth outlook to above 20%, compared to earlier mid-teens guidance, expecting continued momentum through the year.

More News on Earnings Call Transcript

View all

Latest corporate announcements and market updates in Earnings Call Transcript.

View all news
Emcure Pharmaceuticals Reports 24% Revenue Growth and | Stockk News